secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001140361-24-031563
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio reports ELI-002 7P Phase 1a DFS not yet reached at 4.9mg; biomarker responders have no progression
--------------------------------------------------------------------------------

- Median DFS not reached in 14 patients; median follow-up 29.1 weeks.
- At 4.9mg AMP-peptide (n=8), median DFS not reached vs 12.6 weeks for 1.4mg (n=6).
- Patients with tumor biomarker reduction had zero progression events; non-responders had median DFS 11.0 weeks.
- Above-median T cell responders had no progression events as of May 24, 2024 data cutoff.
- Phase 2 interim analysis (135 patients) expected Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000114036124031563/0001140361-24-031563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000114036124031563/ny20031755x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-031563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer